PVLA
HOLD / NEUTRALMeanRevComposite
36.40
Technical
83.40
Fundamental
20.80
Rank
—
Price
143.94
Hurst
0.00
As of
Jul 22, 2026
Daily
Palvella Therapeutics, Inc.
HealthcareBiotechnologyPalvella Therapeutics is a clinical-stage biotech company developing topical treatments for rare genetic skin conditions. Its main candidate is QTORIN rapamycin, a gel formulation currently being tested in Phase 3 trials for microcystic lymphatic malformations and Phase 2 trials for cutaneous venous malformations, with additional development for angiokeratomas and related skin disorders. The company also has a separate candidate, QTORIN pitavastatin, in development for disseminated superficial actinic porokeratosis.
Market cap
$2.2B
P/E (trailing)
—
P/E (forward)
-20.58
PEG ratio
—
Dividend yield
—
Beta
—
52w range
56.22 – 161.38
Return on equity
-46.63%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 151.43 (+156.5%) · range 56.69–157.77
Cycle position
59/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 6 · NOT READY · exit proximity 15
Conviction
20/ 100 · maturity 29%
VScore.1612
Buildup.2842
EMA entry setup.356
Fundamentals.2121
Volume profile
POC
115.35
Price vs POC
+31.3%
Overhead supply
14%
Runway
+0.5%
Value area 102.46–145.42 · 14% of 120d volume overhead · clean runway
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +5.47% | +10.96% | mature |
| 40d | +5.59% | +10.96% | 36/40d |